Meeting
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
Authors
Bei Hu
Levine Cancer Institute, Charlotte, NC
Bei Hu , Patrick Michael Reagan , Laurie Helen Sehn , Jeff Porter Sharman , Mark Hertzberg , Huilai Zhang , Austin Injae Kim , Charles Herbaux , Lysiane Molina , Dai Maruyama , Piotr Smolewski , Frank Stenner , Veronica Craine , Rucha Kothari , Jamie H. Hirata , Deniz Sahin , Matthew Dean Sei Sugidono , Calvin Lee , Herve Tilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03274492
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7518)
DOI
10.1200/JCO.2023.41.16_suppl.7518
Abstract #
7518
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.
First Author: Vivian Nguyen
Poster
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
First Author: Michael Dickinson
Poster
2019 ASCO Annual Meeting
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
First Author: Herve Tilly
Poster
2023 ASCO Annual Meeting
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
First Author: David Lavie